

BIOGRAPHICAL SKETCH

Name: Pierre Laurent-Puig, M.D., PhD	POSITION TITLE Professor of Oncology at the Université Paris Cité, Paris, France; Head of the Cordeliers Research Center Genomics and Cancer Department Director of the SIRIC CARPEM www.carpem.fr ; Director of the Institut du Cancer Paris Carpem President of the Canceropôle Ile-de-France www.Canceropole-idf.fr		
62 years; 3 children			
INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
Faculty of Medicine, University Paris 5, Paris	M.D.	1979-1984	Medicine
Residency in Paris hospitals (AIHP), Faculty of Medicine Paris, France	DES	1984-1990	Specialization in Gastroenterology
University Paris 7, Curie Institute, Paris	PhD	1989-1993	Somatic Genetic Alterations of colon cancer
Fellowship University Paris 11, Faculty of Medicine Le Kremlin-Bicetre		1990-1994	Fellow-ship in digestive cancer
Curie Institute, Paris, France		1994-1997	Postdoctoral Fellowship (Genetic-Oncology)
certified Director of Research Projects (awarded in 2001 by University Paris 5, Paris)	HDR	2001	Oncology

POSITIONS

Current Hospital position

Full Professor (September 2004, Oncology) - Biochemistry Department and Genetics department Hôpital European Georges Pompidou (HEGP).
 Since 2021: Head the Tumor and cancer genomic medicine department of APHP.Centre (Cochin and HEGP Hospitals).

Current Research position

Director of research Unit since 2002 and now head of the department of Genome and Cancer in Cordeliers Research Center, in which I am at the

head of the INSERM research team Personalized medicine, pharmacogenomics and therapeutic optimization.
<https://www.crcordeliers.fr/departement-3/>

Current administrative position

President of canceropôle Ile-de-France www.canceropole-idf.fr

Director of the SIRIC CARPEM www.carpem.fr

Director of the Paris Cancer Institute Paris CARPEM <http://institutducancer-hopitauxcentre-u-paris.aphp.fr>

EDUCATION

After internship and specialist clinical training in gastroenterology, liver disease and digestive tract cancer, I embarked upon scientific studies, namely a doctorate and two years of post-doctoral research work in INSERM Unit 434 (under the direction of G. Thomas at the Curie Institute). My research activities soon turned towards the characterization of somatic, genetic alterations in cancer.


Research interests: Dual training has equipped me for research at the interface between clinic and laboratory. In 1998, I integrated the mixed research INSERM Unit UMR-S490 (directed by Ph. Beaune) and I led in 2002 a research team focusing on correlations between genotype and phenotype in solid human tumors. My research has addressed the identification of new diagnostic and prognostic markers, and more recently, markers for resistance to chemotherapy. Initially, the work focused exclusively on colon cancer and hepatocellular carcinoma but more recently it has been extended to cover malignancies involving lung and pancreatic cancer. We recently developed different methods for characterizing circulating tumor DNA both by sequencing and by digital droplet PCR using specific probes.

ADMINISTRATIVE DUTIES

- Director of the Biological Resources Center EPIGENETEC since 2006
- Former Scientific Director of the cancéropôle Ile-de-France 2014-2020;
- Present president of the board of the cancéropôle Ile-de-France since 2019
- Director of the SIRIC CARPEM (integrated site for cancer research: cancer research for personalized medicine) funded by the INCa (French National Cancer Institute) since 2013.
- Director of the Institut du Cancer de Paris CAREPM since 2018 created by the merging of the 3 hospitals (Georges Pompidou, Cochin and Necker Hospitals) since 2018

PUBLICATIONS

Author of 608 publications including 467 original articles, 141 editorials, letters, and reviews.
H index=91 (ISI web of Knowledge), over 41718 citations excluding self-citations



Selection of publication

10 major publications:

1: Lievre, A; Bachet, JB; Le Corre, D; Boige, V; Landi, B; Emile, JF; Cote, JF; Tomasic, G; Penna, C; Ducreux, M; Rougier, P; Penault-Llorca, F; **Laurent-Puig, P.** KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. **Cancer Res** 2006;66:3992-3995 **Times cited:1791**

2: Lievre, A; Bachet, JB; Boige, V; Cayre, A; Le Corre, D; Buc, E; Ychou, M; Bouche, O; Landi, B; Louvet, C; Andre, T; Bibeau, F; Diebold, MD; Rougier, P; Ducreux, M; Tomasic, G; Emile, JF; Penault-Llorca, F; **Laurent-Puig, P.** KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab **J Clin Oncol** 2008;26:374-379 **Times Cited:1237**

3: Guinney, J; Dienstmann, R; Wang, X; de Reynies, A; Schlicker, A; Sonesson, C; Marisa, L; Roepman, P; Nyamundanda, Giff; Angelino, Paolo; Bot, Brian M.; Morris, Jeffrey S.; Simon, Iris M.; Gerster, Sarah; Fessler, Evelyn; Melo, Felipe De Sousa E.; Missiaglia, Edoardo; Ramay, Hena; Barras, David; Homicsko, Krisztian; Maru, Dipen; Manyam, Ganiraju C.; Broom, Bradley; Boige, Valerie; Perez-Villamil, Beatriz; Laderas, Ted; Salazar, Ramon; Gray, Joe W.; Hanahan, Douglas; Taberner, Josep; Bernards, Rene; Friend, Stephen H.; **Laurent-Puig, P***; Medema, JP*; Sadanandam* A; Delorenzi, M*; Kopetz, S*; Vermeulen, L*; Tejpar, S* The consensus molecular subtypes of colorectal cancer **Nature Med** 2015;21:1350-1356 **Times Cited:2178** * co-senior authors

4: Marisa, L; de Reynies, A; Duval, A; Selves, J; Gaub, MP; Vescovo, L; Etienne-Grimaldi, MC; Schiappa, R; Guenot, D; Ayadi, M; Kirzin, S; Chazal, M; Flejou, JF; Benchimol, D; Berger, A; Lagarde, A; Pencreach, E; Piard, F; Elias, D; Parc, Y; Olschwang, S; Milano, G; **Laurent-Puig, P***; Boige, V* Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic **Plos Med** 2013;10: e1001453 **Times Cited:763** * joint senior authors on this work

5: **Laurent-Puig, P;** Cayre, A; Manceau, G; Buc, E; Bachet, JB; Lecomte, T; Rougier, P; Lievre, A; Landi, B; Boige, V; Ducreux, M; Ychou, M; Bibeau, F; Bouche, O; Reid, J; Stone, S; Penault-Llorca, F. Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer **J Clin Oncol** 2009;27:5924-5930 **Times Cited:576**

6: Taly, V; Pekin, D; Benhaim, L; Kotsopoulos, SK.; Le Corre, D; Li, X; Atochin, I; Link, DR.; Griffiths, A.; Pallier, K; Blons, H; Bouche, O; Landi, B; Hutchison, JB; **Laurent-Puig, P.** Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients **Clin Chem** 2013;59:1722-1731 **Times Cited:362**

7: **Laurent-Puig, P;** Pekin, D; Normand, C; Kotsopoulos, SK.; Nizard, P; Perez-Toralla, K; Rowell, R; Olson, J; Srinivasan, P; Le Corre, D; Hor, T; El Harrak, Z; Li, X; Link, DR.; Bouche, O; Emile, JF; Landi, B; Boige, V; Hutchison, JB; Taly, V Clinical Relevance of KRAS-Mutated Subclones Detected with

Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy **Clin Cancer Res** 2015;21:1087-1097 **Times Cited:118**

8: Pietrasz, D; Pecuchet, N; Garlan, F; Didelot, A; Dubreuil, O; Doat, S; Imbert-Bismut, F; Karoui, M; Vaillant, JC; Taly, V; **Laurent-Puig, P**; Bachet, JB, Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker *Clinical Cancer Res* 2017;23:116-23 **Times Cited:139**

9: Taieb, J; Zaanan, A; Le Malicot, K; Julie, C; Blons, H; Mineur, L; Bennouna, J; Tabernero, J; Mini, E; Folprecht, G; Van Laethem, JL; Lepage, C; Emile, JF; Laurent-Puig, P. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab A Post Hoc Analysis of the PETACC-8 Trial **Jama Oncol** 2016;2:643-652 **Times Cited:104**

10: Bachet, J. B.; Bouche, O.; Taieb, J.; Dubreuil, O.; Garcia, M. L.; Meurisse, A.; Normand, C.; Gornet, J. M.; Artru, P.; Louafi, S.; Bonnetain, F.; Thiot-Bidault, A.; Baumgaertner, I.; Coriat, R.; Tougeron, D.; Lecomte, T.; Mary, F.; Aparicio, T.; Marthey, L.; Taly, V; Blons, H.; Vernerey, D.; Laurent-Puig, P. **Laurent-Puig, P.** RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study **Ann Oncol** 2018;29:1211-1219 **Times Cited:79**

69 Publications as last author

1: Aparicio T, Svrcek M, Henriques J, Afchain P, Lièvre A, Tougeron D, Gagniere J, Terrebonne E, Piessen G, Legoux JL, Lecaille C, Pocard M, Gornet JM, Zaanan A, Lavau-Denes S, Lecomte T, Deutsch D, Vernerey D, **Laurent-Puig P.** Panel gene profiling of small bowel adenocarcinoma, results from the NADEGE prospective cohort. *Int J Cancer*. 2020 Nov 13. doi: 10.1002/ijc.33392. Epub ahead of print. PMID: 33186471. **Times Cited:0**

2: Mouillet-Richard S, **Laurent-Puig P.** YAP/TAZ Signalling in Colorectal Cancer: Lessons from Consensus Molecular Subtypes. *Cancers (Basel)*. 2020;12:E3160. **Times Cited:0**

3: Hofman P, Rouleau E, Sabourin JC, Denis M, Deleuze JF, Barlesi F, **Laurent-Puig P.** Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives. *Cancer Cytopathol*. 2020;128:601-610. PMID: 32885912. **Times Cited:1**

4: Bachet JB, Blons H, Hammel P, Hariry IE, Portales F, Mineur L, Metges JP, Mulot C, Bourreau C, Cain J, Cros J, **Laurent-Puig P.** Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. *Clin Cancer Res*. 2020;26:5208-5216. PMID: 32605910. **Times Cited:0**

5: Taieb J, Jung A, Sartore-Bianchi A, Peeters M, Seligmann J, Zaanan A, Burdon P, Montagut C, **Laurent-Puig P.** The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. *Drugs*. 2019;79:1375-1394. PMID: 31347092. **Times Cited:9**

6: Mas L, Bachet JB, Taly V, Bouché O, Taieb J, Cohen R, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Thiot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D, **Laurent-Puig P.** BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. **Cancers**. 2019;11:998. PMID: 31319569. **Times Cited:6**

7: Boige V, Mollevi C, Gourgou S, Azria D, Seitz JF, Vincent M, Bigot L, Juzyna B, Miran I, Gerard JP, **Laurent-Puig P.** Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial. **Int J Cancer**. 2019;145:3163-3172. PMID: 31107542. **Times Cited:2**

- 8: Tlemsani C, Leroy K, Gimenez-Roqueplo AP, Mansuet-Lupo A, Pasmant E, Larousserie F, Boudou-Rouquette P, Vidaud M, Cadranet J, Blons H, Goldwasser F, **Laurent-Puig P**. Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options. **J Med Genet**. 2020;57:104-108. PMID: 30352869. **Times Cited:4**
- 9: Vaughn CP, Costa JL, Feilotter HE, Petraroli R, Bagai V, Rachiglio AM, Marino FZ, Tops B, Kurth HM, Sakai K, Mafficini A, Bastien RRL, Reiman A, Le Corre D, Boag A, Crocker S, Bihl M, Hirschmann A, Scarpa A, Machado JC, Blons H, Sheils O, Bramlett K, Ligtenberg MJL, Cree IA, Normanno N, Nishio K, **Laurent-Puig P**. Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. **BMC Cancer**. 2018;18:828. PMID: 30115026. **Times Cited:6**
- 10: Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, **Laurent-Puig P**; PETACC8 investigators. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. **Clin Cancer Res**. 2018;24:4745-4753. PMID: 29921730. **Times Cited:5**
- 11: Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thiot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, **Laurent-Puig P**. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. **Ann Oncol**. 2018;29:1211-1219. PMID: 29438522. **Times Cited:53**
- 12: Pugh S, Thiébaud R, Bridgewater J, Grisoni ML, Moutasim K, Rousseau F, Thomas GJ, Griffiths G, Liebaert F, Primrose J, **Laurent-Puig P**. Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. **Oncotarget**. 2017;8:93856-93866. PMID: 29212194; **Times Cited:20**
- 13: Taieb J, Kourie HR, Emile JF, Le Malicot K, Balogoun R, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Mulot C, Bouché O, Aparicio T, Michel P, Thaler J, Bridgewater J, Van Cutsem E, Perkins G, Lepage C, Salazar R, **Laurent-Puig P**; Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 Investigators. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. **JAMA Oncol**. 2018 Jul 12;4(7):e173695. PMID: 29167892; **Times Cited:27**
- 14: Pilati C, Taieb J, Balogoun R, Marisa L, de Reyniès A, **Laurent-Puig P**. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification. **Ann Oncol**. 2017;28:1032-1035. PMID: 28328000. **Times Cited:25**
- 15: Pilati C, Shinde J, Alexandrov LB, Assié G, André T, Hélias-Rodzewicz Z, Ducoudray R, Le Corre D, Zucman-Rossi J, Emile JF, Bertherat J, Letouzé E, **Laurent-Puig P**. Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. **J Pathol**. 2017;24:10-15. PMID: 28127763. **Times Cited:45**
- 16: Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, Levaché CB, Saban-Roche L, Thaler J, Petersen LN, Bridgewater J, Perkins G, Lepage C, Van Cutsem E, Zaanen A, **Laurent-Puig P**; PETACC8 Investigators. Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. **Ann Oncol**. 2017;28:824-830. PMID: 28031175. **Times Cited:22**
- 17: Pécuchet N, Rozenholc Y, Zonta E, Pietrasz D, Didelot A, Combe P, Gibault L, Bachet JB, Taly V, Fabre E, Blons H, **Laurent-Puig P**. Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA. **Clin Chem**. 2016 Nov;62(11):1492-1503. PMID: 27624137. **Times Cited:34**

- 18: Boige V, Vincent M, **Laurent-Puig P**. Women at a Disadvantage in Fluorouracil Treatment-Reply. *JAMA Oncol*. 2016;2:830-1. PMID: 27281626. **Times Cited:0**
- 19: Boige V, Vincent M, Alexandre P, Tejpar S, Landolfi S, Le Malicot K, Greil R, Cuyle PJ, Yilmaz M, Faroux R, Matzdorff A, Salazar R, Lepage C, Taieb J, **Laurent-Puig P**. DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. *JAMA Oncol*. 2016;2:655-662. PMID: 26794347. **Times Cited:16**
- 20: Taieb J, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Lepage C, Emile JF, **Laurent- Puig P**. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. *JAMA Oncol*. 2016;2:643-653. PMID: 26768652. **Times Cited:76**
- 21: Guinney, J; Dienstmann, R; Wang, X; de Reynies, A; Schlicker, A; Sonesson, C; Marisa, L; Roepman, P; Nyamundanda, Giff; Angelino, Paolo; Bot, Brian M.; Morris, Jeffrey S.; Simon, Iris M.; Gerster, Sarah; Fessler, Evelyn; Melo, Felipe De Sousa E.; Missiaglia, Edoardo; Ramay, Hena; Barras, David; Homicsko, Krisztian; Maru, Dipen; Manyam, Ganiraju C.; Broom, Bradley; Boige, Valerie; Perez-Villamil, Beatriz; Laderas, Ted; Salazar, Ramon; Gray, Joe W.; Hanahan, Douglas; Tabernero, Josep; Bernards, Rene; Friend, Stephen H.; **Laurent-Puig, P***; Medema, JP*; Sadanandam* A; Delorenzi, M*; Kopetz, S*; Vermeulen, L*; Tejpar, S* The consensus molecular subtypes of colorectal cancer *Nature Med* 2015;21:1350-1356 **Times Cited:1412** * co-senior authors
- 22: Manceau G, Marisa L, Boige V, Duval A, Gaub MP, Milano G, Selves J, Olschwang S, Jooste V, le Legrain M, Lecorre D, Guenot D, Etienne-Grimaldi MC, Kirzin S, Martin L, Lepage C, Bouvier AM, **Laurent-Puig P**. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. *Cancer Med*. 2015;4:371-82. PMID: 25641861. **Times Cited:16**
- 23: Tops BB, Normanno N, Kurth H, Amato E, Mafficini A, Rieber N, Le Corre D, Rachiglio AM, Reiman A, Sheils O, Noppen C, Lacroix L, Cree IA, Scarpa A, Ligtenberg MJ, **Laurent-Puig P**. Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. *BMC Cancer*. 2015 31;15:26 PMID: 25637035. **Times Cited:33**
- 24: Perkins G, Pilati C, Blons H, **Laurent-Puig P**. Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. *Pharmacogenomics*. 2014;15:1043-52. PMID: 24956256. **Times Cited:14**
- 25: Laforest A, Aparicio T, Zaanan A, Silva FP, Didelot A, Desbeaux A, Le Corre D, Benhaim L, Pallier K, Aust D, Pistorius S, Blons H, Svrcek M, **Laurent-Puig P**. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. *Eur J Cancer*. 2014;50:1740-1746. PMID: 24797764. **Times Cited:49**
- 26: Manceau G, Imbeaud S, Thiébaud R, Liébaert F, Fontaine K, Rousseau F, Génin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouché O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamäki R, Sarhadi V, Knuutila S, Boige V, André T, **Laurent-Puig P**. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. *Clin Cancer Res*. 2014;20:3338-47. PMID: 24771647. **Times Cited:68**
- 27: Aparicio T, Svrcek M, Zaanan A, Beohou E, Laforest A, Afchain P, Mitry E, Taieb J, Di Fiore F, Gornet JM, Thirot-Bidault A, Sobhani I, Malka D, Lecomte T, Locher C, Bonnetain F, **Laurent-Puig P**. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. *Br J Cancer*. 2013;109:3057-66. PMID: 24196786. **Times Cited:56**

- 28: Guinney J, Ferté C, Dry J, McEwen R, Manceau G, Kao KJ, Chang KM, Bendtsen C, Hudson K, Huang E, Dougherty B, Ducreux M, Soria JC, Friend S, Derry J, **Laurent-Puig P**. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. **Clin Cancer Res**. 2014 Jan 1;20(1):265-272. PMID: 24170544. **Times Cited:22**
- 29: Emile JF, Tisserand J, Bergougnoux L, Nowak F, Faucher G, Surel S, Lamy A, Lecorre D, Helias-Rodzewicz Z, Hofman P, Sabourin JC, **Laurent-Puig P**. BRAF EQA Group. Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. **BMC Cancer**. 2013;13:472. PMID: 24119386. **Times Cited:10**
- 30: Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, Atochin I, Link DR, Griffiths AD, Pallier K, Blons H, Bouché O, Landi B, Hutchison JB, **Laurent-Puig P**. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. **Clin Chem**. 2013;59:1722-31. PMID: 23938455. **Times Cited:301**
- 31: Blons H, Rouleau E, Charrier N, Chatellier G, Côté JF, Pages JC, de Fraipont F, Boyer JC, Merlio JP, Morel A, Gorisse MC, de Cremoux P, Leroy K, Milano G, Ouafik L, Merlin JL, Le Corre D, Aucouturier P, Sabourin JC, Nowak F, Frebourg T, Emile JF, Durand-Zaleski I, **Laurent-Puig P**; MOKAECM Collaborative Group. Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience. **PLoS One**. 2013;8:e68945. PMID: 23935912. **Times Cited:18**
- 32: Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi M-C, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Flejou J-F, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, **Laurent-Puig P***, Boige V* . Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value. **Plos Medicine**. 2013; 10. Times Cited: 289 *senior authors **Times Cited:573**
- 33: Taly V, Pekin D, El Abed A, **Laurent-Puig P**. Detecting biomarkers with microdroplet technology. **Trends Mol Med**. 2012;18:405-16. PMID: 22727782. **Times Cited:76**
- 34: Agostini J, Benoist S, Seman M, Julié C, Imbeaud S, Letourneur F, Cagnard N, Rougier P, Brouquet A, Zucman-Rossi J, **Laurent-Puig P**. Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. **J Hepatol**. 2012;56:869-76. PMID: 22200551. **Times Cited:27**
- 35: Corté H, Manceau G, Blons H, **Laurent-Puig P**. MicroRNA and colorectal cancer. **Dig Liver Dis**. 2012;44:195-200. PMID: 22105087. **Times Cited:54**
- 36 Lecomte T, Ceze N, Dorval E, **Laurent-Puig P**. Circulating free tumor DNA and colorectal cancer. **Gastroenterol Clin Biol**. 2010;34:662-81. PMID: 20832215. **Times Cited:44**
- 37: Boige V, Mendiboure J, Pignon JP, Lorient MA, Castaing M, Barrois M, Malka D, Trégouët DA, Bouché O, Le Corre D, Miran I, Mulot C, Ducreux M, Beaune P, **Laurent-Puig P**. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. **J Clin Oncol**. 2010;28:2556-64. PMID: 20385995. **Times Cited:110**
- 38: Lièvre A, Blons H, **Laurent-Puig P**. Oncogenic mutations as predictive factors in colorectal cancer. **Oncogene**. 2010;29:3033-43. PMID: 20383189. **Times Cited:81**
- 39: Perkins G, Lièvre A, Ramacci C, Méatchi T, de Reynies A, Emile JF, Boige V, Tomasic G, Bachet JB, Bibeau F, Bouché O, Penault-Llorca F, Merlin JL, **Laurent-Puig P**. Additional value of

EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. **Int J Cancer**. 2010;127:1321-31. PMID: 20049837. **Times Cited:36**

40: Lièvre A, **Laurent-Puig P**. Genetics: Predictive value of KRAS mutations in chemoresistant CRC. **Nat Rev Clin Oncol**. 2009;6:306-7. PMID: 19483733. **Times Cited:26**

41: Lièvre A, **Laurent-Puig P**. Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies. **Per Med**. 2009;6:145-157. PMID: 29788610. **Times Cited:1**

42: Blons H, Pallier K, Le Corre D, Danel C, Tremblay-Gravel M, Houdayer C, Fabre-Guillevin E, Riquet M, Dessen P, **Laurent-Puig P**. Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. **BMC Med Genomics**. 2008;1:25. PMID: 18549475. **Times Cited:29**

43: de Reyniès A, Boige V, Milano G, Faivre J, **Laurent-Puig P**. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. **J Clin Oncol**. 2008;26:2228-30; author reply 2230-1. PMID: 18445856. **Times Cited:26**

44: Legras A, Lièvre A, Bonaiti-Pellié C, Cottet V, Pariente A, Nalet B, Lafon J, Faivre J, Bonithon-Kopp C, Goasguen N, Penna C, Olschwang S, **Laurent-Puig P**; ANGH group. Mitochondrial D310 mutations in colorectal adenomas: an early but not causative genetic event during colorectal carcinogenesis. **Int J Cancer**. 2008;122:2242-8. PMID: 18224678. **Times Cited:16**

45: Lécuru F, Le Frère Belda MA, Bats AS, Tulpin L, Metzger U, Olschwang S, **Laurent-Puig P**. Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study. **Int J Gynecol Cancer**. 2008;18:1326-31. PMID: 18217965. **Times Cited:31**

46: Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, **Laurent-Puig P**. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. **J Clin Oncol**. 2008;26:374-9. PMID: 18202412. **Times Cited:1134**

47: Zucman-Rossi J, **Laurent-Puig P**. Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. **Pharmacogenomics**. 2007;8:997-1003. PMID: 17716233. **Times Cited:28**

48: Lécuru F, Metzger U, Scarabin C, Le Frère Belda MA, Olschwang S, **Laurent-Puig P**. Hysteroscopic findings in women at risk of HNPCC. Results of a prospective observational study. **Fam Cancer**. 2007;6:295-9. PMID: 17415684. **Times Cited:13**

49: Lièvre A, Milet J, Carayol J, Le Corre D, Milan C, Pariente A, Nalet B, Lafon J, Faivre J, Bonithon-Kopp C, Olschwang S, Bonaiti-Pellié C, **Laurent-Puig P**; members of the ANGH group. Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. **BMC Cancer**. 2006 Nov 24;6:270. doi: 10.1186/1471-2407-6-270. PMID: 17125518. **Times Cited:55**

50: Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, **Laurent-Puig P**. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. **Cancer Res**. 2006;66:3992-5. PMID: 16618717. **Times Cited:1642**

51: Lièvre A, Blons H, Houllier AM, Laccourreye O, Brasnu D, Beaune P, **Laurent-Puig P**. Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma. **Br J Cancer**. 2006;94:692-7. PMID: 16495928. **Times Cited:47**

- 52: Lièvre A, Landi B, Côté JF, Veyrie N, Zucman-Rossi J, Berger A, **Laurent-Puig P**. Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers. **Oncogene**. 2005 Nov 3;24(48):7253-6. doi: 10.1038/sj.onc.1208867. PMID: 16044160. **Times Cited:33**
- 53: Lièvre A, Chapusot C, Bouvier AM, Zinzindohoué F, Piard F, Roignot P, Arnould L, Beaune P, Faivre J, **Laurent-Puig P**. Clinical value of mitochondrial mutations in colorectal cancer. **J Clin Oncol**. 2005;23:3517-25. PMID: 15908662. **Times Cited:117**
- 54: Zinzindohoué F, Lecomte T, Ferraz JM, Houllier AM, Cugnenc PH, Berger A, Blons H, **Laurent-Puig P**. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. **Clin Cancer Res**. 2005;11:594-9. PMID: 15701845. **Times Cited:63**
- 55: Lecomte T, Ferraz JM, Zinzindohoué F, Lorient MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, **Laurent-Puig P**. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. **Clin Cancer Res**. 2004;10:5880-8. PMID: 15355920. **Times Cited:178**
- 56: Zinzindohoué F, Blons H, Hans S, Lorient MA, Houllier AM, Brasnu D, Laccourreye O, Tregouet DA, Stucker I, **Laurent-Puig P**. Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. **Anticancer Res**. 2004;24:2021-6. PMID: 15274394. **Times Cited:30**
- 57: Gad S, Teboul D, Lièvre A, Goasguen N, Berger A, Beaune P, **Laurent-Puig P**. Is the gene encoding Chibby implicated as a tumour suppressor in colorectal cancer ? **BMC Cancer**. 2004;4:31. PMID: 15245581. **Times Cited:10**
- 58: Blons H, Gad S, Zinzindohoué F, Manière I, Beauregard J, Tregouet D, Brasnu D, Beaune P, Laccourreye O, **Laurent-Puig P**. Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. **Clin Cancer Res**. 2004;10:2594-9. PMID: 15102660. **Times Cited:24**
- 59: Ferraz JM, Zinzindohoué F, Lecomte T, Cugnenc PH, Lorient MA, Beaune P, Stucker I, Berger A, **Laurent-Puig P**. Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer. **Int J Cancer**. 2004;110:183-7. PMID: 15069679. **Times Cited:18**
- 60: Blons H, **Laurent-Puig P**. TP53 and head and neck neoplasms. **Hum Mutat**. 2003;21:252-7. PMID: 12619110. **Times Cited:61**
- 61: Lecomte T, Berger A, Zinzindohoué F, Micard S, Landi B, Blons H, Beaune P, Cugnenc PH, **Laurent-Puig P**. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. **Int J Cancer**. 2002;100:542-8. PMID: 12124803. **Times Cited:192**
- 62: Blons H, Laccourreye O, Houllier AM, Carnot F, Brasnu D, Beaune P, Zucman-Rossi J, **Laurent-Puig P**. Delineation and candidate gene mutation screening of the 18q22 minimal region of deletion in head and neck squamous cell carcinoma. **Oncogene**. 2002;21:5016-23. PMID: 12118382. **Times Cited:16**
- 63: Rebischung C, Gérard JP, Gayet J, Thomas G, Hamelin R, **Laurent-Puig P**. Prognostic value of P53 mutations in rectal carcinoma. **Int J Cancer**. 2002;100:131-5. PMID: 12115559. **Times Cited:41**
- 64: Zinzindohoué F, Ferraz JM, **Laurent-Puig P**. Thymidylate synthase promoter polymorphism. **J Clin Oncol**. 2001;19:3442. PMID: 11454897. **Times Cited:17**

- 65: Rosty C, Brière J, Cellier C, Delabesse E, Carnot F, Barbier JP, **Laurent-Puig P**. Association of a duodenal follicular lymphoma and hereditary nonpolyposis colorectal cancer. **Mod Pathol**. 2000;13:586-90. PMID: 10824932. **Times Cited:11**
- 66: Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, **Laurent-Puig P**. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. **J Clin Oncol**. 2000;18:1465-73. PMID: 10735894. **Times Cited:139**
- 67: Coulet F, Blons H, Cabelguenne A, Lecomte T, Laccourreye O, Brasnu D, Beaune P, Zucman J, **Laurent-Puig P**. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. **Cancer Res**. 2000 Feb 1;60(3):707-11. PMID: 10676657. **Times Cited:73**
- 68: Blons H, Radicella JP, Laccourreye O, Brasnu D, Beaune P, Boiteux S, **Laurent-Puig P**. Frequent allelic loss at chromosome 3p distinct from genetic alterations of the 8-oxoguanine DNA glycosylase 1 gene in head and neck cancer. **Mol Carcinog**. 1999;26:254-60. PMID: 10569802. **Times Cited:51**
- 69: Blons H, Cabelguenne A, Carnot F, Laccourreye O, de Waziers I, Hamelin R, Brasnu D, Beaune P, **Laurent-Puig P**. Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. **Int J Cancer**. 1999;84:410-5. PMID: 10404095. **Times Cited:35**

22 Publications as first author

- 1: **Laurent-Puig P**, Grisoni ML, Heinemann V, Liebaert F, Neureiter D, Jung A, Montestruc F, Gaston-Mathe Y, Thiébaud R, Stintzing S. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer. **Clin Cancer Res**. 2019 ;25:134-141. **Times Cited:18**
- 2: **Laurent-Puig P**, Pekin D, Normand C, Kotsopoulos SK, Nizard P, Perez-Toralla K, Rowell R, Olson J, Srinivasan P, Le Corre D, Hor T, El Harrak Z, Li X, Link DR, Bouché O, Emile JF, Landi B, Boige V, Hutchison JB, Taly V. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. **Clin Cancer Res**. 2015;21:1087-97. **Times Cited:103**
- 3: **Laurent-Puig P**, Benhaim L. Surgery: Cetuximab--an option for unresectable CRC liver metastases. **Nat Rev Clin Oncol**. 2013;10:374-5. PMID: 23736647. **Times Cited:1**
- 4: **Laurent-Puig P**, Manceau G, Zucman-Rossi J, Blons H. Dual blockade of epidermal growth factor receptor-induced pathways: a new avenue to treat metastatic colorectal cancer. **J Clin Oncol**. 2012;30:1550-2. PMID: 22412137. **Times Cited:7**
- 5: **Laurent-Puig P**, Manceau G, Boige V, Blons H. Prediction of response to anticancer treatment as simple as the resolution of ordinary differential equations? **Gut**. 2012;61:637-8. PMID: 22203374. **Times Cited:1**
- 6: **Laurent-Puig P**, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. **J Clin Oncol**. 2009;27:5924-30. PMID: 19884556. **Times Cited:529**
- 7: **Laurent-Puig P**, Lièvre A, Blons H. Beyond the KRAS test. **Eur J Cancer**. 2009;45 Suppl 1:398-9. PMID: 19775645.

- 8: **Laurent-Puig P**, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. **Clin Cancer Res**. 2009;15:1133-9. PMID: 19228718. **Times Cited:99**
- 9: **Laurent-Puig P**, Taieb J. Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? **Curr Opin Oncol**. 2008;20:454-8. PMID: 18525343. **Times Cited:13**
- 10: **Laurent-Puig P**, Zucman-Rossi J. Genetics of hepatocellular tumors. **Oncogene**. 2006;25:3778-86. PMID:16799619. **Times Cited:254**
- 11: **Laurent-Puig P**, Plomteux O, Bluteau O, Zinzindohoué F, Jeannot E, Dahan K, Kartheuser A, Chapusot C, Cugnenc PH, Zucman-Rossi J. Frequent mutations of hepatocyte nuclear factor 1 in colorectal cancer with microsatellite instability. **Gastroenterology**. 2003;124:1311-4. PMID: 12730871. **Times Cited:17**
- 12: **Laurent-Puig P**, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. **Gastroenterology**. 2001;120:1763-73. PMID:11375957. **Times Cited:433**
- 13: **Laurent-Puig P**, Blons H, Cugnenc PH. Sequence of molecular genetic events in colorectal tumorigenesis. **Eur J Cancer Prev**. 1999;8 Suppl 1:S39-47. PMID:10772417. **Times Cited:44**
- 14: **Laurent-Puig P**, Bérourd C, Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. **Nucleic Acids Res**. 1998;26:269-70. PMCID: PMC147178. **Times Cited:106**
- 15: **Laurent-Puig P**, Dussaix E, Altman C, Laval C, Stuyver L, Wilber JC, Babany G, Chopineau S, Bedossa P, Brocheriou I, et al. Host and viral characteristics affecting the response to interferon therapy in chronic hepatitis C. **Eur J Gastroenterol Hepatol**. 1995;7:335-40. PMID: 7541297. **Times Cited:7**
- 16: **Laurent-Puig P**, Lubin R, Semhoun-Ducloux S, Pelletier G, Fourre C, Ducreux M, Briantais MJ, Buffet C, Soussi T. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. **Gut**. 1995 Mar;36:455-8. PMID: 7698709. **Times Cited:48**
- 17: **Laurent-Puig P**, Dussaix E, de Paillette L, Ducreux M, Pelletier G, Briantais MJ, Etienne JP, Buffet C. Prevalence of hepatitis C virus RNA in suspected drug induced liver diseases. **J Hepatol**. 1993;19:487-9. PMID: 8151112 **Times Cited:4**
- 18: **Laurent-Puig P**, Flejou JF, Fabre M, Bedossa P, Belghiti J, Gayral F, Franco D. Overexpression of p53: a rare event in a large series of white patients with hepatocellular carcinoma. **Hepatology**. 1992;16:1171-5. PMID: 1330867. **Times Cited:61**
- 19: **Laurent-Puig P**, Boutron A, Briantais MJ, Vahedi K, Fritsch J, Choury AD, Pelletier G, Buffet C. Lipase/amylase ratio in pancreatitis: an etiologic index? **Gastroenterology**. 1992 ;103:353-4. PMID: 1377146. **Times Cited:5**
- 20: **Laurent-Puig P**, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, Validire P, Muleris M, Girodet J, Salmon RJ, et al. Survival and acquired genetic alterations in colorectal cancer. **Gastroenterology**. 1992;102:1136-41. PMID: 1551522. **Times Cited:211**
- 21: **Laurent-Puig P**, Dussaix E, Lecoz Y, Martes P, Buffet C. Prevalence of anti- hepatitis C virus antibodies among patients with alcoholic liver disease, supplemented by 4-RIBA. **Dig Dis Sci**. 1992 Jan;37:156-7. PMID: 1309449. **Times Cited:9**

22: **Laurent-Puig P**, Olschwang S, Delattre O, Validire P, Melot T, Mosseri V, Salmon RJ, Thomas G. Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. *Int J Cancer*. 1991;49:220-3. PMID: 1652568. **Times Cited:64**

53 Publications as 2nd or penultimate author

1: Abdallah, R; Taly, V; Zhao, SL; Pietrasz, D; Bachet, JB; Basile, D; Mas, L; Zaanani, A; **Laurent-Puig, P**; Taieb, J. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. *Cancer Treat. Rev*. 2020;87:-. **Times Cited:0**

2: Moati, E; Blons, H; Taly, V; Garlan, F; Wang-Renault, SF; Pietrasz, D; Didelot, A; Garrigou, S; Saint, A; Pernot, S; Taieb, J; **Laurent-Puig, P**; Zaanani, A. Plasma clearance ofRASmutation under therapeutic pressure is a rare event in metastatic colorectal cancer. *Int. J. Cancer* 2020;147:1185-1189. **Times Cited:1**

3: Le Corre, D; Ghazi, A; Balogoun, R; Pilati, C; Aparicio, T; Martin-Lannereee, S; Marisa, L; Djouadi, F; Poindessous, V; Crozet, C; Emile, JF; Mulot, C; Le Malicot, K; Boige, V; Blons, H; de Reynies, A; Taieb, J; Ghiringhelli, F; Bennouna, J; Launay, JM; **Laurent-Puig, P**; Mouillet-Richard, S. The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. *EBioMedicine* 2019;46:94-104. **Times Cited:2**

4: Bruzzi, M; Auclin, E; Lo Dico, R; Voron, T; Karoui, M; Espin, E; Cianchi, F; Weitz, J; Buggenhout, A; Malafosse, R; Denimal, F; Le Malicot, K; Vernerey, D; Douard, R; Emile, JF; Lepage, C; **Laurent-Puig, P**; Taieb, J. Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial. *Ann. Surg. Oncol*. 2019;26:3561-3567. **Times Cited:0**

5: Perkins, G; Svrcek, M; Bouchet-Doumenq, C; Voron, T; Colussi, O; Debove, C; Merabtene, F; Dumont, S; Sauvanet, A; Hammel, P; Cros, J; Andre, T; Bachet, JB; Bardier, A; Douard, R; Meatchi, T; Peschard, F; Emile, JF; Cojean-Zelek, I; **Laurent-Puig, P**; Taieb, J. Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. *Br. J. Cancer* 2019;120:697-702. **Times Cited:2**

6: Garinet, S; **Laurent-Puig, P**; Blons, H; Oudart, JB. Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?. *J. Clin. Med*. 2018;7:-. **Times Cited:21**

7: Legras, A; Barritault, M; Tallet, A; Fabre, E; Guyard, A; Rance, B; Digan, W; Pecuchet, N; Giroux-Leprieur, E; Julie, C; Jouveshomme, S; Duchatelle, V; Giraudet, V; Gibault, L; Cazier, A; Pastre, J; Le Pimpec-Barthes, F; **Laurent-Puig, P**; Blons, H. Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer Results of a 2-Year Experience on 1343 Samples. *J. Mol. Diagn*. 2018;20:550-564. **Times Cited:7**

8: Moati, E; Taly, V; Didelot, A; Perkins, G; Blons, H; Taieb, J; **Laurent-Puig, P**; Zaanani, A. Role of circulating tumor DNA in the management of patients with colorectal cancer. *Clin. Res. Hepatol. Gastroenterol*. 2018;42:396-402. **Times Cited:4**

9: Lievre, A; Merlin, JL; Sabourin, JC; Artru, P; Tong, S; Libert, L; Audhuy, F; Gicquel, C; Moureau-Zabotto, L; Ossendza, RA; **Laurent-Puig, P**; Ducreux, M. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014. *Dig. Liver Dis*. 2018;50:507-512. **Times Cited:8**

- 10: Zaanan, A; Shi, Q; Taieb, J; Alberts, SR; Meyers, JP; Smyrk, TC; Julie, C; Zawadi, A; Tabernero, J; Mini, E; Goldberg, RM; Folprecht, G; Van Laethem, JL; Le Malicot, K; Sargent, DJ; **Laurent-Puig, P**; Sinicrope, FA. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy A Pooled Analysis From 2 Randomized Clinical Trials. **JAMA Oncol.** 2018;4:379-383. **Times Cited:38**
- 11: Legras, A; Pecuchet, N; Imbeaud, S; Pallier, K; Didelot, A; Roussel, H; Gibault, L; Fabre, E; Le Pimpec-Barthes, F; **Laurent-Puig, P**; Blons, H. Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer. **Cancers** 2017;9:-. **Times Cited:43**
- 12: Emile, JF; Julie, C; Le Malicot, K; Lepage, C; Tabernero, J; Mini, E; Folprecht, G; Van Laethem, JL; Dimet, S; Boulagnon-Rombi, C; Allard, MA; Penault-Llorca, F; Bennouna, J; **Laurent-Puig, P**; Taieb, J. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. **Eur. J. Cancer** 2017;82:16-24. **Times Cited:19**
- 13: Garlan, F; **Laurent-Puig, P**; Sefrioui, D; Siauve, N; Didelot, A; Sarafan-Vasseur, N; Michel, P; Perkins, G; Mulot, C; Blons, H; Taieb, J; Di Fiore, F; Taly, V; Zaanan, A. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). **Clin. Cancer Res.** 2017;23:5416-5425. **Times Cited:71**
- 14: Pecuchet, N; Vieira, T; Rabbe, N; Antoine, M; Blons, H; Cadranel, J; **Laurent-Puig, P**; Wislez, M. Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities. **Ann. Oncol.** 2017;28:1597-1604. **Times Cited:12**
- 15: Mamzer, MF; Duchange, N; Sylviane, D; Marvanne, P; Rambaud, C; Marsico, G; Cerisey, C; Scotte, F; Burgun, A; Badoual, C; **Laurent-Puig, P**; Herve, C. Partnering with patients in translational oncology research: ethical approach. **J. Transl. Med.** 2017;15:-. **Times Cited:4**
- 16: Taieb, J; Le Malicot, K; Shi, Q; Penault-Llorca, F; Bouche, O; Tabernero, J; Mini, E; Goldberg, RM; Folprecht, G; Van Laethem, JL; Sargent, DJ; Alberts, SR; Emile, JF; **Laurent-Puig, P**; Sinicrope, FA. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. **JNCI-J. Natl. Cancer Inst.** 2017;109:-. **Times Cited:80**
- 17: Pietrasz, D; Pecuchet, N; Garlan, F; Didelot, A; Dubreuil, O; Doat, S; Imbert-Bismut, F; Karoui, M; Vaillant, JC; Taly, V; **Laurent-Puig, P**; Bachet, JB. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. **Clin. Cancer Res.** 2017;23:116-123. **Times Cited:93**
- 18: Zonta, E; Garlan, F; Pecuchet, N; Perez-Toralla, K; Caen, O; Milbury, C; Didelot, A; Fabre, E; Blons, H; **Laurent-Puig, P**; Taly, V. Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations. **PLoS One** 2016;11:-. **Times Cited:50**
- 19: Becht, E; de Reynies, A; Giraldo, NA; Pilati, C; Buttard, B; Lacroix, L; Selves, J; Sautes-Fridman, C; **Laurent-Puig, P**; Fridman, WH. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. **Clin. Cancer Res.** 2016;22:4057-4066. **Times Cited:181**
- 20: Gallois, C; **Laurent-Puig, P**; Taieb, J. Methylator phenotype in colorectal cancer: A prognostic factor or not?. **Crit. Rev. Oncol./Hematol.** 2016;99:74-80. **Times Cited:25**
- 21: Pecuchet, N; **Laurent-Puig, P**; Mansuet-Lupo, A; Legras, A; Alifano, M; Pallier, K; Didelot, A; Gibault, L; Danel, C; Just, PA; Riquet, M; Le Pimpec-Barthes, F; Damotte, D; Fabre, E; Blons, H. Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer. **Oncotarget** 2017;8:23831-23840. **Times Cited:26**

- 22: Harle, A; Salleron, J; Perkins, G; Pilati, C; Blons, H; **Laurent-Puig, P**; Merlin, JL. Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers. **Br. J. Cancer** 2015;113:680-685. **Times Cited:6**
- 23: Blons, H; Emile, JF; Le Malicot, K; Julie, C; Zaanan, A; Tabernero, J; Mini, E; Folprecht, G; Van Laethem, JL; Thaler, J; Bridgewater, J; Norgard-Petersen, L; Van Cutsem, E; Lepage, C; Zawadi, MA; Salazar, R; **Laurent-Puig, P**; Taieb, J. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. **Ann. Oncol.** 2014;25:2378-2385. **Times Cited:59**
- 24: Taieb, J; Tabernero, J; Mini, E; Subtil, F; Folprecht, G; Van Laethem, JL; Thaler, J; Bridgewater, J; Petersen, LN; Blons, H; Collette, L; Van Cutsem, E; Rougier, P; Salazar, R; Bedenne, L; Emile, JF; **Laurent-Puig, P**; Lepage, C. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. **Lancet Oncol.** 2014;15:862-873. **Times Cited:142**
- 25: Bats, AS; Blons, H; Narjoz, C; Le Frere-Belda, MA; **Laurent-Puig, P**; Lecuru, F. Microsatellite Instability Analysis in Uterine Cavity Washings to Detect Endometrial Cancer in Lynch Syndrome. **Anticancer Res.** 2014;34:3211-3215. **Times Cited:0**
- 26: Bats, AS; Roussel, H; Narjoz, C; Le Frere-Belda, MA; Chamming's, F; Blons, H; **Laurent-Puig, P**; Lecuru, F. Microsatellite Instability Analysis for the Screening of Synchronous Endometrial and Ovarian Cancer in Lynch Syndrome. **Anticancer Res.** 2013;33:3977-3981. **Times Cited:4**
- 27: Benhaim, L; Gerger, A; Bohanes, P; Paez, D; Wakatsuki, T; Yang, D; LaBonte, MJ; Ning, Y; El-Khoueiry, R; Loupakis, F; Zhang, W; **Laurent-Puig, P**; Lenz, HJ. Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluorouracil chemotherapy. **Pharmacogenomics J.** 2014;14:135-141. **Times Cited:9**
- 28: Manceau, G; Letouze, E; Guichard, C; Didelot, A; Cazes, A; Corte, H; Fabre, E; Pallier, K; Imbeaud, S; Le Pimpec-Barthes, F; Zucman-Rossi, J; **Laurent-Puig, P**; Blons, H. Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma. **Int. J. Cancer** 2013;132:2217-2221. **Times Cited:43**
- 29: Didelot, A; Le Corre, D; Luscan, A; Cazes, A; Pallier, K; Emile, JF; **Laurent-Puig, P**; Blons, H. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. **Exp. Mol. Pathol.** 2012;92:275-280. **Times Cited:83**
- 30: Pallier, K; Cessot, A; Cote, JF; Just, PA; Cazes, A; Fabre, E; Danel, C; Riquet, M; Devouassoux-Shisheboran, M; Ansieau, S; Puisieux, A; **Laurent-Puig, P**; Blons, H. TWIST1 a New Determinant of Epithelial to Mesenchymal Transition in EGFR Mutated Lung Adenocarcinoma. **PLoS One** 2012;7:-. **Times Cited:43**
- 31: Pallier, K; Cazes, A; El Khattabi, L; Lecchi, C; Desroches, M; Danel, C; Riquet, M; Fabre-Guillevin, E; **Laurent-Puig, P**; Blons, H. DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma. **Tumor Biol.** 2012;33:41-51. **Times Cited:3**
- 32: Bouquier, J; Blons, H; Narjoz, C; Lecuru, F; **Laurent-Puig, P**; Bats, AS. Microsatellite instability analysis in uterine cavity washings as a screening tool for endometrial cancer in Lynch syndrome. **Fam. Cancer** 2011;10:655-657. **Times Cited:4**

- 33: Blouin, JM; Bortoli, S; Nacfer, M; Collinet, M; Penot, G; **Laurent-Puig, P**; Forest, C. Down-regulation of the phosphoenolpyruvate carboxykinase gene in human colon tumors and induction by omega-3 fatty acids. **Biochimie** 2010;92:1772-1777. **Times Cited:8**
- 34: Goasguen, N; de Chaisemartin, C; Brouquet, A; Julie, C; Prevost, GP; **Laurent-Puig, P**; Penna, C. Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and in vitro response to chemotherapeutic agents. **Int. J. Cancer** 2010;127:1028-1037. **Times Cited:19**
- 35: Pallier, K; Houllier, AM; Le Corre, D; Cazes, A; **Laurent-Puig, P**; Blons, H. No Somatic Genetic Change in the Paxillin Gene in Nonsmall-Cell Lung Cancer. **Mol. Carcinog.** 2009;48:581-585. **Times Cited:11**
- 36: Barault, L; Veyrie, N; Jooste, V; Lecorre, D; Chapusot, C; Ferraz, JM; Lievre, A; Cortet, M; Bouvier, AM; Rat, P; Roignot, P; Faivre, J; **Laurent-Puig, P**; Piard, F. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. **Int. J. Cancer** 2008;122:2255-2259. **Times Cited:240**
- 37: Cote, JF; Kirzin, S; Krarnar, A; Mosnier, JF; Diebold, MD; Soubeyran, I; Thirouard, AS; Selves, J; **Laurent-Puig, P**; Ychou, M. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. *Clin. Cancer Res.* 2007;13:3269-3275. **Times Cited:108**
- 38: Boyault, S; Rickman, DS; de Reynies, A; Balabaud, C; Rebouissou, S; Jeannot, E; Herault, A; Saric, J; Belghiti, J; Franco, D; Bioulac-Sage, P; **Laurent-Puig, P**; Zucman-Rossi, J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. **Hepatology** 2007;45:42-52. **Times Cited:648**
- 39: Blons, H; Cote, JF; Le Corre, D; Riquet, M; Fabre-Guilevin, E; **Laurent-Puig, P**; Danel, C. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. **Am. J. Surg. Pathol.** 2006;30:1309-1315. **Times Cited:72**
- 40: Lecomte, T; Cellier, C; Meatchi, T; Barbier, JP; Cugnenc, PH; Jian, R; **Laurent-Puig, P**; Landi, B. Chromoendoscopic Colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. **Clin. Gastroenterol. Hepatol.** 2005;3:897-902. **Times Cited:93**
- 41: Rebouissou, S; Rosty, C; Lecuru, F; Boisselier, S; Bui, H; Le Frere-Belfa, MA; Sastre, X; **Laurent-Puig, P**; Zucman-Rossi, J. Mutation of TCF1 encoding hepatocyte nuclear factor 1 alpha in gynecological cancer. *Oncogene* 2004;23:7588-7592. **Times Cited:18**
- 42: Chevrier, I; Stucker, I; Houllier, AM; Cenee, S; Beaune, P; **Laurent-Puig, P**; Lorient, MA. Myeloperoxidase: new polymorphisms and relation with lung cancer risk. **Pharmacogenetics** 2003;13:729-739. **Times Cited:36**
- 43: Bluteau, O; Jeannot, E; Bioulac-Sage, P; Marques, JM; Blanc, JF; Bui, H; Beaudoin, JC; Franco, D; Balabaud, C; **Laurent-Puig, P**; Zucman-Rossi, J. Bi-allelic inactivation of TCF1 in hepatic adenomas. *Nature Genet.* 2002;32:312-315. **Times Cited:226**
- 44: Magne, N; Fischel, JL; Dubreuil, A; Formento, P; Poupon, MF; **Laurent-Puig, P**; Milano, G. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD 1839 ('Iressa'). **Br. J. Cancer** 2002;86:1518-1523. **Times Cited:200**
- 45: Bluteau, O; Beaudoin, JC; Pasturaud, P; Belghiti, J; Franco, D; Bioulac-Sage, P; **Laurent-Puig, P**; Zucman-Rossi, J. Specific association between alcohol intake, high grade of differentiation

and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. **Oncogene** 2002;21:1225-1232. **Times Cited:48**

46: Cabelguenne, A; Lorient, MA; Stucker, I; Blons, H; Koum-Besson, E; Brasnu, D; Beaune, P; Laccourreye, O; **Laurent-Puig, P**; De Waziers, I. Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. **Int. J. Cancer** 2001;93:725-730. **Times Cited:47**

47: Rosty, C; Chazal, M; Etienne, MC; Letoublon, C; Bourgeon, A; Delpero, JR; Pezet, D; Beaune, P; **Laurent-Puig, P**; Milano, G. Determination of microsatellite instability, p53 and K-ras mutations in hepatic metastases from patients with colorectal cancer: Relationship with response to 5-fluorouracil and survival. **Int. J. Cancer** 2001;95:162-167. **Times Cited:40**

48: Gallagher, WM; Greene, LM; Ryan, MP; Sierra, V; Berger, A; **Laurent-Puig, P**; Conseiller, E. Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. **FEBS Lett.** 2001;489:59-66. **Times Cited:56**

49: Legoix, P; Bluteau, O; Bayer, J; Perret, C; Balabaud, C; Belghiti, J; Franco, D; Thomas, G; **Laurent-Puig, P**; Zucman-Rossi, J. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. **Oncogene** 1999;18:4044-4046. **Times Cited:133**

50: Olschwang, S; Slezak, P; Roze, M; Jaramillo, E; Nakano, H; Koizumi, K; Rubio, CA; **Laurent-Puig, P**; Thomas, G. Somatically acquired genetic alterations in flat colorectal neoplasias. **Int. J. Cancer** 1998;77:366-369. **Times Cited:40**

51: Terris, B; **Laurent-Puig, P**; Belghiti, J; Degott, C; Henin, D; Flejou, JF. Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in France. **Int. J. Cancer** 1997;74:614-619. **Times Cited:29**

52: Boige, V; **Laurent-Puig, P**; Fouchet, P; Flejou, JF; Monges, G; Bedossa, P; Bioulac-Sage, P; Capron, F; Schmitz, A; Olschwang, S; Thomas, G. Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. **Cancer Res.** 1997;57:1986-1990. **Times Cited:137**

53: Stoppa-Lyonnet, D; **Laurent-Puig, P**; Essioux, L; Pages, S; Ithier, G; Ligoñ, L; Fourquet, A; Salmon, RJ; Clough, KB; Pouillart, P; Alapetite, C; Alepee, B; Klijanienko, J; Asselain, B; Beuzeboc, P; Bourgeois, D; Bourgeois, H; Boursstyn, E; Brunin, F; Campana, F; Chauveinc, F; Cosset, JM; deCremoux, P; delaRocheFordiere, A; Delattre, C; deMargerie, V; deStGaudens, AB; Dieras, V; Dorval, T; Dubray, B; Durand, JC; Falcou, MC; Fitoussi, F; GarciaGiralt, E; Giraud, P; Gautier, C; Guglielmina, JN; Hamelin, JP; Hoffman, H; Jaulerry, C; Jouve, M; Labeta, C; Legall, M; Magdelenat, H; Meunier, M; Mosseri, V; NGuyen, TT; Natali, JC; Neuenschwander, S; Nos, C; Olivier, L; Palangie, T; Pierga, JY; Pontvert, D; Roge, P; SastreGareau, X; Schlienger, P; Scholl, S; Selinger, R; Thibault, F; This, P; Trophilme, D; Validire, P; Vielh, P; Vilcoq, JR; VincentSalomon, A; Voillemot, N; Zafrani, B; BonaitiPellie, C; Thomas, G. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. **Am. J. Hum. Genet.** 1997;60:1021-1030. **Times Cited:135**